CC-122 + itraconazole

**CC-122 + itraconazole** is a combination of two drugs: avadomide (CC-122), a novel cereblon E3 ligase modulator (CELMoD) with immunomodulatory and anti-neoplastic properties; and itraconazole, a triazole-class antifungal agent. - **Avadomide (CC-122)** binds to cereblon in the cullin 4 E3 ubiquitin ligase complex, promoting ubiquitination and degradation of the transcription factors Aiolos and Ikaros, leading to increased apoptosis of malignant B-cells, T-cell activation, and modulation of interferon-response and cytokine gene expression. It is under development primarily for B-cell lymphomas[3][5]. - **Itraconazole** inhibits fungal 14α-demethylase, blocking ergosterol synthesis and resulting in fungal cell membrane destabilization. It is used to treat a range of fungal infections, including blastomycosis, histoplasmosis, aspergillosis, and onychomycosis[2][4][6]. The specific combination "CC-122 + itraconazole" does not correspond to an approved co-formulation or fixed-dose product but refers to the concurrent use of avadomide and itraconazole, potentially in the context of clinical trials or management of fungal infections in immunocompromised patients receiving CC-122.

Brand names

SporanoxTolsuraOnmel

Other names

avadomideCC-122CC122CC 122itraconazole